Developer docs
API playgroundTry for free, no card

Search company profiles

Axion BioSystems

Full company profile

uuid000295w

Namestring
Axion BioSystems
Legal namestring
Axion BioSystems, Inc.
Company typeenum
Private
Founded yearint
2008
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersAtlanta, United States
HQ citystring
Atlanta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
live-cell analysis, microelectrode arrays, electrophysiology platforms, impedance-based assays, cardiac safety testing
Industry3 codes
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
NAICS code4 codes
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
  • Analytical Laboratory Instrument Manufacturing334516
  • Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals334515
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code3 codes
  • Laboratory Analytical Instruments3826
  • Industrial Instruments For Measurement, Display, And Control3823
  • Instruments For Meas & Testing Of Electricity & Elec Signals3825
Product category
Live-cell Analysis Instrumentation
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Hardware Systems
TypeHardware Sales
Description

Sale of Maestro MEA instruments (Pro, Edge, Volt), Maestro Z platforms, and Omni/Lux imaging systems. Hardware platforms serve as the foundation for recurring consumables revenue.

axionbiosystems.com
2MEA Plates and Consumables
TypeHardware Sales
Description

Recurring revenue from proprietary plate formats including BioCircuit MEA plates, CytoView MEA plates, Organoid MEA plates, Lumos MEA plates, and SpheroGuide MEA plates in various well formats.

axionbiosystems.com
3Software Licenses and Subscriptions
TypeSubscription Recurring
Description

AxIS software modules for neural, cardiac, impedance, and imaging analysis. Axion Portal cloud subscription for AI-powered data analysis with tiered modules.

axionbiosystems.com
4Axion Insights Lab Services
TypeProfessional Services
Description

Contract research services offering Maestro MEA assay services from study design through data analysis, delivering actionable electrophysiology insights.

axionbiosystems.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Pricing details4 tiers
1Maestro Pro - High-throughput MEA system for research labs
ModelOtherBilling cadenceMulti-year contract
Notes

Enterprise pricing through quote request; includes base system plus modules for specific assay types (Neural, Cardiac, Viability, Automation)

axionbiosystems.com
2Maestro Edge - MEA and live-cell analysis system
ModelOtherBilling cadenceMulti-year contract
Notes

Enterprise pricing through quote request; mid-throughput option for labs needing flexibility

axionbiosystems.com
3Maestro Z - Impedance-based live-cell analysis
ModelOtherBilling cadenceMulti-year contract
Notes

Enterprise pricing through quote request; includes Impedance Module and optional GxP compliance module

axionbiosystems.com
4Axion Portal Cloud Analysis - AI-powered imaging software
ModelSubscriptionBilling cadenceAnnual
Notes

Cloud-based subscription model with analysis modules including Clonogenic Assay, Confluency, Fluorescence, iPSC, Organoid Analysis, and Scratch Assay modules

axionbiosystems.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Maestro
Description

Multi-electrode array (MEA) platform for real-time, label-free live-cell analysis including Maestro Pro, Maestro Edge, and Maestro Volt systems.

axionbiosystems.com
+5 more records
Core offering1 text field

Axion BioSystems develops and manufactures Multiwell Microelectrode Array (MEA) and impedance-based live-cell analysis platforms that record electrical and functional activity from neurons, cardiomyocytes, and other cells in real time without labels or dyes. Its Maestro Pro/Edge/Volt MEA systems, Maestro Z impedance systems, and Omni/Lux incubator-compatible imaging systems are sold to pharmaceutical companies and academic researchers along with proprietary MEA plates, Axion Portal cloud AI software, and Axion Insights Lab contract research services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduced animal testing through human iPSC-based cardiac safety assays accepted by FDA
+2 more records
Product overview1 text field

Axion BioSystems offers a comprehensive live-cell analysis platform comprising three core technology lines: Maestro MEA (Microelectrode Array) systems for electrophysiology recording from neurons and cardiomyocytes; Maestro Z platforms for impedance-based live-cell analysis; and Omni/Lux imaging systems for automated brightfield and fluorescence live-cell imaging. These platforms are supported by specialized software modules (Neural, Cardiac, Viability, Impedance, GxP, Automation) and a cloud-based Axion Portal with AI-powered analysis. The product portfolio includes specialized consumables (MEA plates in various formats including BioCircuit, CytoView, Lumos, SpheroGuide, and Organoid MEA plates) and is complemented by the Axion Insights Lab service for contract research. Recent acquisitions of CytoTronics (high-density CMOS MEA technology) and CytoSMART Technologies expand capabilities in live-cell imaging and high-throughput single-cell resolution screening.

Product and service14 records
1Maestro Pro
CategoryMEA instrument platform
Description

High-throughput Multiwell Microelectrode Array (MEA) and live-cell analysis system for recording electrical activity from neurons and cardiomyocytes in real time with label-free, noninvasive measurements across 24-, 48-, and 96-well formats.

2Maestro Edge
CategoryMEA instrument platform
Description

MEA and live-cell analysis system designed for mid-throughput applications with flexible configuration options for neural and cardiac assays.

3Maestro Volt
CategoryMEA instrument platform
Description

MEA system optimized for high-quality voltage measurements with enhanced signal resolution for demanding electrophysiology applications.

4Maestro Z
CategoryImpedance-based live-cell analysis platform
Description

Live-cell analysis system that tracks cellular health, barrier function, proliferation, viability, and cytotoxicity using label-free, impedance-based assays.

5Maestro ZHT
CategoryImpedance-based live-cell analysis platform
Description

High-throughput impedance-based live-cell analysis system for accelerated cellular assays.

6Maestro TrayZ
CategoryImpedance-based live-cell analysis platform
Description

Multiplate live-cell analysis system for processing multiple plates with impedance-based cellular analysis.

7Omni
CategoryImaging platform
Description

Multiwell live-cell analysis platform with brightfield and fluorescence imaging performed from inside the incubator for uninterrupted longitudinal studies.

8Lux
CategoryImaging platform
Description

Single-well live-cell analysis with brightfield and fluorescent imaging from the incubator for smaller scale experiments.

9Lumos
CategoryOptogenetic stimulation accessory
Description

Standalone multiwell optical stimulation device supporting 24-, 48-, or 96-well plates with up to four wavelengths (blue, green, orange, red) for optogenetic experiments when paired with Maestro Pro or Edge systems.

10Axion Portal
CategoryCloud-based AI analysis software
Description

Cloud-based AI-powered software platform built on Microsoft Azure for monitoring, analyzing, and sharing live-cell imaging data with real-time insights, cloud-enabled parallel processing, and automated user alerts.

11Axion Insights Lab
CategoryContract research services
Description

Contract research service offering Maestro MEA assay services from study design through data analysis, delivered by in-house electrophysiology experts.

12MEA Creator Kit
CategoryCustom MEA development kit
Description

Custom MEA development kit enabling researchers to create custom microelectrode array configurations for specialized applications.

13Exact FL
CategoryCell counting instrument
Description

Automated brightfield and fluorescent cell counter with smart counting capabilities for cells and organoids.

14Corning Cell Counter
CategoryCell counting instrument
Description

Automated cell counting solution offered in partnership with Corning for cell enumeration.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-24
Description

Acquired high-density CMOS microelectrode array technology from CytoTronics (originally developed at Harvard University). The acquisition adds more than 13 million nanoscale, multimodal sensors distributed across 96-well and 384-well microplates, enabling high-throughput screening at single-cell resolution for neural and cardiac drug discovery applications.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-21
Description

Acquired by Axion BioSystems in March 2022 to expand capabilities in stem cell research, immuno-oncology, and drug discovery. CytoSMART's live-cell imaging analysis technology complements Axion's MEA portfolio, enhancing the company's offerings in live-cell analysis for life sciences research.

Strategic tierCoreTypeTechnology or Integration
Description

Technology origin institution for the CytoTronics CMOS MEA technology acquired by Axion. The high-density CMOS microelectrode array platform was originally developed at Harvard University before being commercialized through CytoTronics.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Nanion makes MEA, patch-clamp, and impedance-based live-cell analysis platforms (e.g., CardioExcyte 96, SyncroPatch) used in cardiac safety and ion-channel research. It directly competes with Axion's Maestro MEA and Maestro Z lines for the same pharma and academic electrophysiology and CiPA budgets.

TypeDirect peer
Description

MaxWell Biosystems commercializes high-density CMOS microelectrode array technology (MaxOne, MaxTwo) for single-cell and network-level neural recordings. It competes head-to-head with Axion's newly acquired CytoTronics-derived high-density CMOS MEA platform in pharma and academic neuroscience.

TypeDirect peer
Description

Molecular Devices (part of Danaher) sells the Axion-adjacent MEA platform (legacy AxIS-style products) plus patch-clamp (IonWorks), imaging, and screening instruments. It is a long-standing competitor in electrophysiology and cell-based assay screening for pharma.

TypeBroad incumbent
Description

Agilent is a broad life-science and cell-analysis incumbent (xCELLigence, Seahorse, BioTek) and was the counterparty in Axion's 2026 patent settlement. It competes in real-time cell analysis and overlaps with Axion's impedance-based Maestro Z platform.

TypeBroad incumbent
Description

Sartorius (including legacy IntelliCyt) provides cell analysis and live-cell imaging platforms for bioprocessing and pharma R&D. It competes for the same cell-based assay and bioprocess-monitoring budgets as Axion's impedance and imaging products.

TypeBroad incumbent
Description

Thermo Fisher offers cell analysis instruments, lab automation, and reagents across pharma and academic markets. Its CellInsight, Attune, and automation portfolios compete broadly with Axion's instrument-and-consumables stack.

TypeBroad incumbent
Description

Revvity provides life-science reagents, cell imaging, and high-content screening platforms (including legacy Nexcelom cell counting). It competes with Axion's Omni/Lux imaging and cell counting offerings for similar pharma and academic use cases.

TypeBroad incumbent
Description

Tecan sells laboratory automation, readers, and imaging systems (Spark, Infinite, Fluent) widely used in pharma screening. Its imaging and plate-reader portfolio overlaps with Axion's assay readouts and competes for shared lab automation budgets.

TypeEmerging player
Description

Hamilton provides automated liquid handling and integrated cell-analysis workflows that pair with MEA and impedance readers. It is an integration partner and indirect competitor for Axion's MEA Automation Module and impedance automation offerings.

10Corning Life Sciences
TypeOthers
Description

Corning supplies cell-culture consumables, microplates, and a co-branded cell counter distributed by Axion. As a consumables and labware supplier, Corning is an ecosystem partner and adjacent commercial channel rather than a direct MEA competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Axion BioSystems

Live-cell Analysis Instrumentationaxionbiosystems.com

Axion BioSystems firmographics

Firmographics
Name
Axion BioSystems
Legal name
Axion BioSystems, Inc.
Website
https://axionbiosystems.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Axion BioSystems industry classification

Industry
Product category
Live-cell Analysis Instrumentation
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Analytical Laboratory Instrument Manufacturing (334516), Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals (334515), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Laboratory Analytical Instruments (3826), Industrial Instruments For Measurement, Display, And Control (3823), Instruments For Meas & Testing Of Electricity & Elec Signals (3825)
akta.pro industry
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • Live-cell analysis
  • Microelectrode arrays
  • Electrophysiology platforms
  • Impedance-based assays
  • Cardiac safety testing

Where Axion BioSystems is headquartered

Location

Headquarters

HQ city
Atlanta
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Axion BioSystems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Hardware Systems: Sale of Maestro MEA instruments (Pro, Edge, Volt), Maestro Z platforms, and Omni/Lux imaging systems. Hardware platforms serve as the foundation for recurring consumables revenue.
  2. MEA Plates and Consumables: Recurring revenue from proprietary plate formats including BioCircuit MEA plates, CytoView MEA plates, Organoid MEA plates, Lumos MEA plates, and SpheroGuide MEA plates in various well formats.
  3. Software Licenses and Subscriptions: AxIS software modules for neural, cardiac, impedance, and imaging analysis. Axion Portal cloud subscription for AI-powered data analysis with tiered modules.
  4. Axion Insights Lab Services: Contract research services offering Maestro MEA assay services from study design through data analysis, delivering actionable electrophysiology insights.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractMaestro Pro - High-throughput MEA system for research labs
OtherMulti-year contractMaestro Edge - MEA and live-cell analysis system
OtherMulti-year contractMaestro Z - Impedance-based live-cell analysis
SubscriptionAnnualAxion Portal Cloud Analysis - AI-powered imaging software

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Axion BioSystems product offering

Product offering

Core offering

Axion BioSystems develops and manufactures Multiwell Microelectrode Array (MEA) and impedance-based live-cell analysis platforms that record electrical and functional activity from neurons, cardiomyocytes, and other cells in real time without labels or dyes. Its Maestro Pro/Edge/Volt MEA systems, Maestro Z impedance systems, and Omni/Lux incubator-compatible imaging systems are sold to pharmaceutical companies and academic researchers along with proprietary MEA plates, Axion Portal cloud AI software, and Axion Insights Lab contract research services.

Product overview

Axion BioSystems offers a comprehensive live-cell analysis platform comprising three core technology lines: Maestro MEA (Microelectrode Array) systems for electrophysiology recording from neurons and cardiomyocytes; Maestro Z platforms for impedance-based live-cell analysis; and Omni/Lux imaging systems for automated brightfield and fluorescence live-cell imaging. These platforms are supported by specialized software modules (Neural, Cardiac, Viability, Impedance, GxP, Automation) and a cloud-based Axion Portal with AI-powered analysis. The product portfolio includes specialized consumables (MEA plates in various formats including BioCircuit, CytoView, Lumos, SpheroGuide, and Organoid MEA plates) and is complemented by the Axion Insights Lab service for contract research. Recent acquisitions of CytoTronics (high-density CMOS MEA technology) and CytoSMART Technologies expand capabilities in live-cell imaging and high-throughput single-cell resolution screening.

Differentiator

Problem solved

Functional benefit

Brands

  • Maestro: Multi-electrode array (MEA) platform for real-time, label-free live-cell analysis including Maestro Pro, Maestro Edge, and Maestro Volt systems.
  • Axion Insights Lab
  • Axion Portal
  • Lumos
  • Omni
  • Lux

Products and services

  • Maestro Pro High-throughput Multiwell Microelectrode Array (MEA) and live-cell analysis system for recording electrical activity from neurons and cardiomyocytes in real time with label-free, noninvasive measurements across 24-, 48-, and 96-well formats.
  • Maestro Edge MEA and live-cell analysis system designed for mid-throughput applications with flexible configuration options for neural and cardiac assays.
  • Maestro Volt MEA system optimized for high-quality voltage measurements with enhanced signal resolution for demanding electrophysiology applications.
  • Maestro Z Live-cell analysis system that tracks cellular health, barrier function, proliferation, viability, and cytotoxicity using label-free, impedance-based assays.
  • Maestro ZHT High-throughput impedance-based live-cell analysis system for accelerated cellular assays.
  • Maestro TrayZ Multiplate live-cell analysis system for processing multiple plates with impedance-based cellular analysis.
  • Omni Multiwell live-cell analysis platform with brightfield and fluorescence imaging performed from inside the incubator for uninterrupted longitudinal studies.
  • Lux Single-well live-cell analysis with brightfield and fluorescent imaging from the incubator for smaller scale experiments.
  • Lumos Standalone multiwell optical stimulation device supporting 24-, 48-, or 96-well plates with up to four wavelengths (blue, green, orange, red) for optogenetic experiments when paired with Maestro Pro or Edge systems.
  • Axion Portal Cloud-based AI-powered software platform built on Microsoft Azure for monitoring, analyzing, and sharing live-cell imaging data with real-time insights, cloud-enabled parallel processing, and automated user alerts.
  • Axion Insights Lab Contract research service offering Maestro MEA assay services from study design through data analysis, delivered by in-house electrophysiology experts.
  • MEA Creator Kit Custom MEA development kit enabling researchers to create custom microelectrode array configurations for specialized applications.
  • Exact FL Automated brightfield and fluorescent cell counter with smart counting capabilities for cells and organoids.
  • Corning Cell Counter Automated cell counting solution offered in partnership with Corning for cell enumeration.

Quantifiable outcome

  • Reduced animal testing through human iPSC-based cardiac safety assays accepted by FDA
  • +2 more outcomes

Companies that use Axion BioSystems

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Axion BioSystems technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature7 records

Axion BioSystems partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • CytoTronicscoreTechnology or Integration · 24 January 2026Acquired high-density CMOS microelectrode array technology from CytoTronics (originally developed at Harvard University). The acquisition adds more than 13 million nanoscale, multimodal sensors distributed across 96-well and 384-well microplates, enabling high-throughput screening at single-cell resolution for neural and cardiac drug discovery applications.
  • CytoSMART TechnologiescoreStrategic or Co-development Partner · 21 March 2022Acquired by Axion BioSystems in March 2022 to expand capabilities in stem cell research, immuno-oncology, and drug discovery. CytoSMART's live-cell imaging analysis technology complements Axion's MEA portfolio, enhancing the company's offerings in live-cell analysis for life sciences research.
  • Harvard UniversitycoreTechnology or IntegrationTechnology origin institution for the CytoTronics CMOS MEA technology acquired by Axion. The high-density CMOS microelectrode array platform was originally developed at Harvard University before being commercialized through CytoTronics.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Axion BioSystems competitors and assessment

Company assessment

Direct peers

  • Nanion Technologies: Nanion makes MEA, patch-clamp, and impedance-based live-cell analysis platforms (e.g., CardioExcyte 96, SyncroPatch) used in cardiac safety and ion-channel research. It directly competes with Axion's Maestro MEA and Maestro Z lines for the same pharma and academic electrophysiology and CiPA budgets.
  • MaxWell Biosystems: MaxWell Biosystems commercializes high-density CMOS microelectrode array technology (MaxOne, MaxTwo) for single-cell and network-level neural recordings. It competes head-to-head with Axion's newly acquired CytoTronics-derived high-density CMOS MEA platform in pharma and academic neuroscience.
  • Molecular Devices: Molecular Devices (part of Danaher) sells the Axion-adjacent MEA platform (legacy AxIS-style products) plus patch-clamp (IonWorks), imaging, and screening instruments. It is a long-standing competitor in electrophysiology and cell-based assay screening for pharma.

Broad incumbents

  • Agilent Technologies: Agilent is a broad life-science and cell-analysis incumbent (xCELLigence, Seahorse, BioTek) and was the counterparty in Axion's 2026 patent settlement. It competes in real-time cell analysis and overlaps with Axion's impedance-based Maestro Z platform.
  • Sartorius: Sartorius (including legacy IntelliCyt) provides cell analysis and live-cell imaging platforms for bioprocessing and pharma R&D. It competes for the same cell-based assay and bioprocess-monitoring budgets as Axion's impedance and imaging products.
  • Thermo Fisher Scientific: Thermo Fisher offers cell analysis instruments, lab automation, and reagents across pharma and academic markets. Its CellInsight, Attune, and automation portfolios compete broadly with Axion's instrument-and-consumables stack.
  • Revvity (formerly PerkinElmer): Revvity provides life-science reagents, cell imaging, and high-content screening platforms (including legacy Nexcelom cell counting). It competes with Axion's Omni/Lux imaging and cell counting offerings for similar pharma and academic use cases.
  • Tecan: Tecan sells laboratory automation, readers, and imaging systems (Spark, Infinite, Fluent) widely used in pharma screening. Its imaging and plate-reader portfolio overlaps with Axion's assay readouts and competes for shared lab automation budgets.

Emerging players

  • Hamilton Company: Hamilton provides automated liquid handling and integrated cell-analysis workflows that pair with MEA and impedance readers. It is an integration partner and indirect competitor for Axion's MEA Automation Module and impedance automation offerings.

Others

  • Corning Life Sciences: Corning supplies cell-culture consumables, microplates, and a co-branded cell counter distributed by Axion. As a consumables and labware supplier, Corning is an ecosystem partner and adjacent commercial channel rather than a direct MEA competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Axion BioSystems social profiles

Digital presence

Axion BioSystems compliance and trust

Trust signal

Compliance1 record

Axion BioSystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Axion BioSystems leadership team

Management profile

Number of profiles

Profiles4 records

Axion BioSystems subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Axion BioSystems funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Axion BioSystems M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Axion BioSystems

What does Axion BioSystems do?

Axion BioSystems develops and manufactures Multiwell Microelectrode Array (MEA) and impedance-based live-cell analysis platforms that record electrical and functional activity from neurons, cardiomyocytes, and other cells in real time without labels or dyes. Its Maestro Pro/Edge/Volt MEA systems, Maestro Z impedance systems, and Omni/Lux incubator-compatible imaging systems are sold to pharmaceutical companies and academic researchers along with proprietary MEA plates, Axion Portal cloud AI software, and Axion Insights Lab contract research services.

Is Axion BioSystems a public or private company?

Axion BioSystems is a private company. It is classified as corporate owned and is currently operating.

When was Axion BioSystems founded?

Axion BioSystems was founded in 2008. It employs 101 to 250 people.

Where is Axion BioSystems based?

Axion BioSystems is headquartered in Atlanta, United States, in the North America region.

How does Axion BioSystems make money?

Four revenue lines are on record. Hardware Systems are the primary driver. The others are MEA Plates and Consumables, software Licenses and Subscriptions and axion Insights Lab Services.

Who are Axion BioSystems's main competitors?

Direct peers on record are Nanion Technologies, MaxWell Biosystems and Molecular Devices. Broad incumbents are Agilent Technologies, Sartorius, Thermo Fisher Scientific, Revvity (formerly PerkinElmer) and Tecan. Hamilton Company is listed as an emerging player. Corning Life Sciences is listed as an others.

Does Axion BioSystems have an API?

Yes. The MEA Automation Module provides an API for interfacing with liquid handling platforms, enabling automation of Cardiac and Neural MEA assays. The Impedance Automation Module also offers an API for automating impedance assays with liquid handling platform integration. Developer documentation is at axionbiosystems.com/products/mea/mea-software/mea-automation-module.

What industry is Axion BioSystems in?

Axion BioSystems's product category is Live-cell Analysis Instrumentation. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments, with a secondary code of HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS). Its NAICS code is 33451 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogAxion BioSystems Introduces Synexus, Bringing Single-Cell Resolution to High-Throughput Functional Cell AnalysisAxion BioSystems launched Synexus, a configurable platform combining microelectrode array, high-density MEA, and electrical imaging for single-cell resolution in high-throughput functional cell analysis. The system records from up to 96 wells with over 138,000 electrodes per well, and 384-well capacity is coming soon.FinancialContent Business PageAxion BioSystems Introduces Synexus, Bringing Single-Cell Resolution to High-Throughput Functional Cell AnalysisAxion BioSystems launched Synexus, a configurable live-cell analysis platform combining microelectrode array, high-density MEA, and electrical imaging. It offers single-cell resolution with over 138,000 electrodes per well and up to 96-well recording, with 384-well support coming soon. The platform aims to connect functional and morphological data for disease research and drug discovery.Business Wire BlogAxion BioSystems and Agilent Technologies Resolve LitigationAxion BioSystems and Agilent Technologies resolved two pending lawsuits in Delaware under a confidential settlement, with neither party admitting liability. Axion CEO Julien Bradley said the resolution has no impact on its products or business, and the company will continue marketing and developing its live-cell analysis tools.Law360Agilent, Axion End Cell Analysis IP Suit After Jury SelectionLaboratory equipment company Agilent Technologies and biotechnology company Axion BioSystems have agreed to settle a patent infringement lawsuit over cell analysis technology, ending the dispute just before jury selection was set to begin on Monday. The companies reached a resolution prior to trial, with no details on settlement terms disclosed. The case was scheduled to proceed in court as reported by Law360.PharmiWeb.comMaestro MEA Platform Powers First Stem Cell Cardiac Safety Assay in FDA ISTAND ProgramAxion BioSystems announced that the FDA's Center for Drug Evaluation and Research has accepted the company's letter of intent into the ISTAND Program for its Human iPSC-Cardiomyocyte MEA Assay, making it the first stem cell-derived functional cardiac safety assay accepted into this program. The assay combines human induced pluripotent stem cell-derived cardiomyocytes with Axion's Maestro multielectrode array technology to measure cardiac electrophysiology and detect proarrhythmic risk, offering a human-relevant alternative to traditional animal-based testing methods. The company will now work with the FDA to develop a Qualification Plan that, if successful, could enable broader regulatory acceptance of stem cell-based cardiac safety data across drug development programs.Business Wire BlogMaestro MEA Platform Powers First Stem Cell Cardiac Safety Assay in FDA ISTAND ProgramThe FDA's Center for Drug Evaluation and Research (CDER) has accepted Axion BioSystems' letter of intent into the ISTAND Program for its Human iPSC-Cardiomyocyte MEA Assay, marking the first stem cell-derived functional cardiac safety assay accepted into the program. The assay combines human induced pluripotent stem cell-derived cardiomyocytes with Axion's Maestro multielectrode array technology to detect cardiac electrophysiology risks, offering a human-relevant alternative to traditional animal-based testing methods. Axion will now work with the FDA to develop a Qualification Plan that could enable broader regulatory acceptance of stem cell-derived cardiac safety data across drug development programs.Pulse 2.0Axion BioSystems Buys CytoTronics’ High Density CMOS Microelectrode Array Platform For Drug DiscoveryAxion BioSystems has acquired the intellectual property and assets of CytoTronics, gaining high-density CMOS microelectrode array technology originally developed at Harvard University to expand its portfolio of live-cell bioelectronic assay and imaging systems. The deal adds more than 13 million nanoscale, multimodal sensors distributed across 96-well and 384-well microplates, enabling high-throughput screening at single-cell resolution for neural and cardiac drug discovery applications. Axion, founded in 2008 and headquartered in Atlanta, Georgia, with offices in the Netherlands, UK, and China, expects the acquisition to complement its existing MEA and impedance platforms without sacrificing throughput.Business Wire BlogAxion BioSystems Acquires High-Throughput, High-Density CMOS MEA Technology from CytoTronicsAxion BioSystems has acquired the intellectual property and assets of CytoTronics, Inc., integrating its high-density CMOS microelectrode array technology into Axion's product suite. This acquisition enables high-throughput, single-cell-level functional screening for disease research and drug discovery using over 13 million nanoscale sensors distributed across standard microplates. The deal positions Axion to commercialize next-generation assays for neural and cardiac applications, leveraging its existing hardware and software infrastructure.YahooAxion BioSystems Welcomes Biotech Industry Leader Julien Bradley as New CEOAxion BioSystems appointed Julien Bradley as CEO on October 5, 2023. Bradley previously led RedShift BioAnalytics and Quanterix, bringing nearly 20 years of biotech leadership. He will build on Axion's growth in stem cell research and drug discovery.BioSpaceCytoSMART Technologies Joins the Axion BioSystems BrandAxion BioSystems announced full integration of CytoSMART Technologies into its brand, following its 2022 acquisition. The integration will sell CytoSMART's live-cell imaging platforms, such as the Omni, under the Axion banner. The move aims to create a complete lab solution for researchers in stem cell biology, immuno-oncology, and other fields.